Sort   by:  
 Page size 
UnknownNeutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Not available
S-EPMC9757903 | biostudies-literature
UnknownAntibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.
Not available
S-EPMC8927425 | biostudies-literature
UnknownVasopressor use after noncardiac surgery: an international observational study.
Not available
S-EPMC12799376 | biostudies-literature
UnknownExtended pharmacological thromboprophylaxis and clinically relevant venous thromboembolism after major abdominal and pelvic surgery: international, prospective, propensity score-weighted cohort study.
Not available
S-EPMC11894929 | biostudies-literature
UnknownEfficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.
Not available
S-EPMC8693692 | biostudies-literature
Sort   by:  
 Page size